Most Read News

Indian investors not only want a better investing environment, but also more investment options to choose from

Earnings before interest, tax, depreciation, and amortisation more than doubled to ₹208.5 crore in Q3 FY26 from ₹103 crore reported a year earlier.

Revenue from operations for the quarter slipped 2.7% year on year to ₹34,075.8 crore, down from ₹35,031.2 crore recorded in the year ago period

As India presented the Union Budget 2026, market participants approached the policy event with a measured mix of caution and focus, shaped by a decade of uneven equity market reactions to budget announcements.

The company posted a net profit of ₹323.8 crore for the quarter ended December 2025

According to the Finance Minister, the Bio Pharma Shakti initiative is designed to support research, manufacturing capacity, innovation, and scale across the bio pharma value chain.

The fall in fiscal deficit in December 2025 was more due to front-loading of advance tax receipts

Earnings before interest, tax, depreciation and amortisation rose 18% year on year to ₹292.5 crore, up from ₹247.7 crore reported in Q3 of the previous financial year.

Along expected lines, the Union Budget has expanded defence spending and kept the fisc in control

The change is aimed at simplifying the investment process for overseas based Indians and improving ease of access to India’s domestic capital markets.